本文選題：普拉洛芬 + 玻璃酸鈉　； 參考：《中國藥房》2016年35期

【摘要】：目的:探討普拉洛芬聯(lián)合玻璃酸鈉治療中重度干眼癥的有效性和安全性。方法:將180例中重度干眼癥患者按隨機數(shù)字表法分為觀察組和對照組,各90例。對照組患者常規(guī)采用玻璃酸鈉滴眼液,每次1滴,tid,同時采用清潔眼瞼、熱敷及瞼板腺按摩等物理治療;觀察組患者在對照組治療基礎(chǔ)上加用普拉洛芬滴眼液,每次1滴,tid,2周為1個療程。比較兩組患者治療前后的單眼角膜熒光素染色評分、淚膜破裂時間(BUT)、干眼癥狀評分、淚液分泌試驗Ⅰ(SIT)結(jié)果,并據(jù)此評價兩組患者的臨床療效;同時,觀察兩組患者的不良反應(yīng)發(fā)生情況。結(jié)果:治療2、4周后,兩組患者的單眼角膜熒光素染色評分、干眼癥狀評分均明顯低于治療前,BUT和SIT均明顯長于治療前,且治療4周后各指標均明顯優(yōu)于治療2周后;觀察組患者治療2、4周后各指標均明顯優(yōu)于同期對照組,差異均有統(tǒng)計學(xué)意義(P0.05)。觀察組患者的有效率為94.44%,明顯高于對照組的78.89%,差異有統(tǒng)計學(xué)意義(P0.05)。兩組患者在用藥過程中僅出現(xiàn)不同程度的眼部刺激癥狀,未出現(xiàn)其他嚴重的并發(fā)癥,且眼部刺激癥狀評分各分數(shù)段組間比較,差異均無統(tǒng)計學(xué)意義(P0.05)。結(jié)論:普拉洛芬聯(lián)合玻璃酸鈉治療中重度干眼癥患者,能明顯控制眼表炎癥、提高淚膜穩(wěn)定性,療效確切,且具有較高的安全性。
[Abstract]:Objective: to investigate the efficacy and safety of Praprofen combined with sodium hyaluronate in the treatment of moderate and severe dry eye disease. Methods: 180 patients with moderate and severe xerophthalmia were randomly divided into observation group (n = 90) and control group (n = 90). The patients in the control group were routinely treated with sodium hyaluronate eye drops, 1 tid at a time, while the patients in the observation group were given physical therapy such as clean eyelid, hot compress and eyelid gland massage, while the patients in the observation group were treated with Praprofen eye drops on the basis of the treatment in the control group. A course of treatment was given for 2 weeks. The results of corneal fluorescein staining, tear film rupture time, dry eye score and tear secretion test 鈪，

本文編號：1921872